

Graphene-based materials as platforms for skin disease treatment

Filipa A. L. S. Silva

Filipa A. L. S. Silva^{1,2}, Raquel Costa-Almeida^{1,2}, Licinia Timochenco³, Sara I. Amaral^{1,2,3}, Soraia Pinto^{1,2,4}, Inês C. Gonçalves^{1,2}, José Ramiro Fernandes^{5,6}, Fernão D. Magalhães³, Bruno Sarmento^{1,2,7}, Artur M. Pinto^{1,2,3}

¹i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; ²INEB - Instituto de Engenharia Biomédica, Porto, Portugal. ³LEPABE, Faculdade de Engenharia, Universidade do Porto, Porto, Portugal; ⁴ICBAS – Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal; ⁵CQVR – Centro de Química Vila Real, Universidade de Trás-os-Montes e Alto Douro, Portugal; ⁶Physical Department, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal; ⁷CESPU, IINFACTS – Institute for Research and Advanced Training in Health Sciences and Technologies, Gandra, Portugal.

flsilva@i3s.up.pt; arturp@i3s.up.pt

Abstract

Skin diseases are one of the leading causes of global disease burden, affecting millions of people worldwide. In the United States of America (USA), nearly 85 million people are seen by a physician for at least 1 skin disease every year. Guidelines for treatment of Psoriasis, Atopic Dermatitis (AD), and Vitiligo include as first or second line options phototherapy with ultraviolet radiation combined or not with drugs while for Basal Cell Carcinoma (BCC), photodynamic therapy (PDT) with photosensitizers activated by near-infrared (NIR) radiation are listed in the first line of treatments. [1-3] However, these treatments still present limitations due to the low stability, toxicity, and skin penetration of commonly used drugs. Graphene-based materials (GBM) properties allow targeted drug delivery, sustained release, improved biostability and, low toxicity. In addition, they possess a high coefficient extinction in near-infrared (NIR) region making them good candidates to act as photothermal agents. [4]

In this study, we propose the use of nanographene oxide (GON) and reduced nanographene oxide (rGON) as platforms for skin diseases treatment. GO was produced from graphite (Gt) powder through the modified Hummer's method, [4] and further sonicated and centrifuged to obtain GON. This material was later photo-reduced to obtain rGON. Gt water dispersions stabilized with Pluronic P-123 (Gt-P-123) were also prepared. Particle size and morphology were evaluated by transmission electron microscopy (TEM), optic microscopy, and using a zetasizer; zeta potential was also measured. Absorbance spectra (200-850 nm) were obtained using a UV-Vis spectrophotometer. GON and rGON were irradiated with a LED source of 812 nm (150 mW cm⁻²) and temperature increase recorded using a thermocouple. GON and rGON biocompatibility with primary human fibroblasts (HFF-1) was evaluated using the Alamar Blue assay. The permeability of GON, rGON and Gt-P-123 water suspensions through human skin was determined using a Franz cell system.

Single layer GON and rGO were obtained with average lateral dimensions below 200 nm. GON and rGON dispersions showed colloidal stability with zeta potential values of -39.4 ± 1.8 and -37.8 ± 1.2 mV (neutral pH), respectively. rGON temperature reached 59.4 °C after 30 min irradiation, around 1.3-fold higher than GON heating. GON and rGON (100-500 µg mL⁻¹) did not affect HFF-1 cell viability after 24 h of incubation. Both materials were able to cross epidermis and dermis in a time-dependent manner. Skin permeability of rGON revealed to be lower and slower than GON permeability, during the 1st hour of contact with the skin. After 6 h, the amount of rGON that permeated to the receptor compartment was 1.2-fold lower than for GON. Gt-P-123 presented sizes between a few to hundreds (agglomerates) of microns. Due its large size, no skin permeation was observed for Gt-P-123.

These results demonstrate for the first time the potential of GBM for use in skin disease treatment, as biocompatible photothermal agents able to penetrate deep into skin.

Acknowledgements

This work was financed by FEDER funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by national funds (PIDDAC) through FCT/MCTES in the framework of the project POCI-01-0145-FEDER-031143, and Base Funding - UIDB/00511/2020 of the Laboratory for Process Engineering, Environment, Biotechnology and Energy – LEPABE. Artur Pinto thanks the Portuguese Foundation for Science and Technology (FCT) for the financial support of his work contract through the Scientific Employment Stimulus - Individual Call – [CEECIND/03908/2017].

REFERENCES

- [1] Eichenfield, L.F., et al., J Am Acad Dermatol, 70 (2014) 338-351.
- [2] Taieb, A., et al., Brit J Dermatol, 168 (2013) 5-19.
- [3] Menter, A., et al., J Am Acad Dermatol, 58 (2008) 826-850.
- [4] Costa-Almeida, R., et al., Polymers, 12 (2020), 1840.